Loading…

Amplification and Quantification of an Antisense Oligonucleotide from Target microRNA Using Programmable DNA and a Biological Nanopore

This paper describes a strategy for autonomous diagnoses of cancers using microRNA (miRNA) and therapy for tumor cells by DNA computing techniques and nanopore measurement. Theranostics, which involves the combination of diagnosis and therapy, has emerged as an approach for personalized medicine or...

Full description

Saved in:
Bibliographic Details
Published in:Analytical chemistry (Washington) 2017-02, Vol.89 (4), p.2312-2317
Main Authors: Hiratani, Moe, Ohara, Masayuki, Kawano, Ryuji
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This paper describes a strategy for autonomous diagnoses of cancers using microRNA (miRNA) and therapy for tumor cells by DNA computing techniques and nanopore measurement. Theranostics, which involves the combination of diagnosis and therapy, has emerged as an approach for personalized medicine or point-of-care cancer diagnostics. DNA computing will become a potent tool for theranostics because it functions completely autonomously without the need for external regulations. However, conventional theranostics using DNA computing involves a one-to-one reaction in which a single input molecule generates a single output molecule; the concentration of the antisense drug is insufficient for the therapy in this type of reaction. Herein we developed an amplification system involving an isothermal reaction in which a large amount of the antisense DNA drug was autonomously generated after detecting miRNA from small cell lung cancer. In addition, we successfully quantified the amount of the generated drug molecule by nanopore measurement with high accuracy, which was more accurate than conventional gel electrophoresis. This autonomous amplification strategy is a potent candidate for a broad range of theranostics using DNA computing.
ISSN:0003-2700
1520-6882
DOI:10.1021/acs.analchem.6b03830